Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Hold" from Analysts

Shares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have been given an average rating of "Hold" by the twenty-two ratings firms that are currently covering the firm, Marketbeat reports. Sixteen research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $129.35.

Several brokerages have commented on BPMC. Guggenheim set a $132.00 price objective on shares of Blueprint Medicines in a research report on Tuesday. Morgan Stanley boosted their target price on shares of Blueprint Medicines from $102.00 to $129.00 and gave the stock an "equal weight" rating in a research note on Thursday. Jefferies Financial Group assumed coverage on shares of Blueprint Medicines in a report on Monday, March 17th. They set a "buy" rating and a $135.00 price target for the company. Needham & Company LLC downgraded Blueprint Medicines from a "buy" rating to a "hold" rating and set a $130.00 price objective on the stock. in a report on Monday, June 2nd. Finally, JPMorgan Chase & Co. restated a "neutral" rating and set a $129.00 price objective (down previously from $130.00) on shares of Blueprint Medicines in a research report on Monday, June 2nd.

Insider Buying and Selling

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $101.75, for a total transaction of $231,379.50. Following the sale, the chief operating officer now owns 66,992 shares of the company's stock, valued at approximately $6,816,436. This represents a 3.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Ariel Hurley sold 2,752 shares of the company's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $103.13, for a total transaction of $283,813.76. Following the sale, the insider now directly owns 16,944 shares in the company, valued at $1,747,434.72. This trade represents a 13.97% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,574 shares of company stock valued at $1,465,528 over the last 90 days. 4.21% of the stock is owned by insiders.

Institutional Trading of Blueprint Medicines

Large investors have recently modified their holdings of the stock. Cerity Partners LLC bought a new position in Blueprint Medicines during the fourth quarter worth $291,000. Stephens Inc. AR acquired a new position in shares of Blueprint Medicines during the fourth quarter valued at about $321,000. Bank of New York Mellon Corp boosted its position in shares of Blueprint Medicines by 2.4% during the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock worth $26,465,000 after purchasing an additional 7,101 shares in the last quarter. KBC Group NV grew its stake in shares of Blueprint Medicines by 63.9% in the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock valued at $229,000 after buying an additional 1,023 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in Blueprint Medicines in the 4th quarter valued at about $21,104,000.

Blueprint Medicines Price Performance

BPMC traded down $0.05 during trading on Wednesday, hitting $127.85. 3,067,543 shares of the stock traded hands, compared to its average volume of 1,110,342. Blueprint Medicines has a twelve month low of $73.04 and a twelve month high of $128.24. The company has a market cap of $8.26 billion, a price-to-earnings ratio of -118.38 and a beta of 0.84. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The business has a 50 day moving average price of $95.59 and a 200 day moving average price of $95.88.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The firm had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. During the same quarter in the prior year, the firm earned $1.40 earnings per share. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. Equities research analysts forecast that Blueprint Medicines will post -1.28 earnings per share for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.